Halozyme Therapeutics Inc (NASDAQ:HALO) price on Thursday, May 22, fall -0.33% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $53.75.
A look at the stock’s price movement, the close in the last trading session was $53.93. The PE ratio in trailing twelve months stood at 14.26. Turning to its 52-week performance, $70.50 and $42.01 were the 52-week high and 52-week low respectively. Overall, HALO moved -7.98% over the past month.
Halozyme Therapeutics Inc’s market cap currently stands at around $6.62 billion, with investors looking forward to this quarter’s earnings report slated for in June.
Turning to the stock’s technical picture we see that short term indicators suggest on average that HALO is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 6 recommend HALO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 0.50, with HALO’s current price about -7.99% and -10.75% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.85, while 7-day volatility ratio is 1.18% and 7.87% in the 30-day chart. Further, Halozyme Therapeutics Inc (HALO) has a beta value of 1.20, and an average true range (ATR) of 3.25. Analysts have given the company’s stock an average 52-week price target of $62, forecast between a low of $62 and high of $62. Looking at the price targets, the low is -15.35% off current price level while to achieve the yearly target high, price needs to move -15.35%. Nonetheless, investors will most likely welcome a -15.35% jump to $62 which is the analysts’ median price.
If we refocus on Halozyme Therapeutics Inc (NASDAQ:HALO), historical trading data shows that trading volumes averaged 2.14 million over the past 3 months. The company’s latest data on shares outstanding shows there are 123.17 million shares.
The 1.10% of Halozyme Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 100.36% of the company’s shares. Current price change has pushed the stock 12.42% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the HALO stock continues to rise going into the next quarter.
